Antigenic and immunogenic spectrum of foot-and-mouth disease vaccine strain O1Campos against representative viruses of topotypes that circulated in Asia over the past decade

Identifying vaccine strains to control outbreaks of foot-and-mouth disease virus that could spread to new regions is essential for contingency plans. This is the first report on the antigenic/immunogenic relationships of the South American O1/Campos vaccine strain with representative isolates of the...

Full description

Saved in:
Bibliographic Details
Published in:Vaccine 2017-04, Vol.35 (18), p.2303
Main Authors: S Galdo Novo, Malirat, V, Maradei, ED, Espinoza, A M, Smitsaart, E, Pedemonte, A R, Mattion, N, Bergmann, I E
Format: Article
Language:English
Subjects:
Antigens
Circulation
Contingency
Contingency plans
Cross-protection
Disease control
Emergencies
Epidemics
Expectancy
Foot & mouth disease
Immunization
Immunogenicity
Neutralization
Outbreaks
Protected species
Vaccines
Viruses
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Identifying vaccine strains to control outbreaks of foot-and-mouth disease virus that could spread to new regions is essential for contingency plans. This is the first report on the antigenic/immunogenic relationships of the South American O1/Campos vaccine strain with representative isolates of the three currently active Asian type O topotypes. Virus neutralization tests using O1/Campos post-vaccination sera derived from cattle and pigs predicted for both species acceptable cross-protection, even after single vaccination, established by r1 values and by expectancy of protection using monovalent or polyvalent vaccines. The results indicate that effective oil vaccines containing the O1/Campos strain can be used against Asian isolates, expanding the scope of O1/Campos strain included in vaccine banks to control emergencies caused by Asian viruses, even on single-dose vaccination, and to cover the need of effective vaccines in Asia during systematic vaccination.
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2017.03.026